Skip to main content

Table 2 Demographic data of analyzed 244 patients who underwent cisplatin-based chemotherapies

From: A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study

  All patients Pretreatment eGFR
≥60 mL/min/1.73m2
Pretreatment eGFR
< 60 mL/min/1.73m2
Pretreatment
eGFR ≥60
mL/min/1.73m2
(n = 119)
Pretreatment
eGFR < 60
mL/min/1.73m2
(n = 125)
p Bilateral
functioning
kidneys
(n = 83)
Solitary
functioning
kidney
(n = 36)
p Bilateral
functioning
kidneys
(n = 45)
Solitary
functioning
kidney
(n = 80)
p
Age < 70 78 (65.5%) 63 (50.4%) 0.016 49 (58.9%) 29 (80.5%) 0.039 20 (44.4%) 43 (53.7%) 0.32
≥70 41 (34.4%) 62 (49.6%)   34 (41.1%) 7 (19.5%)   25 (55.6%) 37 (46.3%)  
PS 0-1 111 (93.2%) 117 (93.6%) 0.91 77 (92.7%) 34 (94.4%) 0.94 42 (93.3%) 75 (93.8%) 0.083
2-4 8 (6.7%) 8 (6.4%)   6 (7.3%) 2 (5.6%)   3 (6.7%) 5 (6.2%)  
Sex Male 86 (72.3%) 87 (69.6%) 0.64 61 (73.5%) 25 (69.4%) 0.65 32 (71.1%) 55 (68.7%) 0.78
Female 33 (27.7%) 38 (30.4%)   22 (26.5%) 11 (30.6%)   13 (28.9%) 25 (31.3%)  
Comorbidities yes 15 (12.6%) 17 (14.2%) 0.81 13 (15.7%) 2 (5.6%) 0.12 8 (17.8%) 9 (11.2%) 0.36
no / unknown 104 (87.4%) 108 (86.4%)   70 (84.3%) 34 (94.4%)   37 (82.2%) 71 (88.8%)  
DM 3 (2.5%) 4 (3.2%)   2 (2.4%) 1 (2.7%)   2 (4.4%) 2 (2.4%)  
Glomerulonephritis 1 (0.8%) 1 (0.8%)   1 (1.2%) 0 (0.0%)   0 (0.0%) 1 (1.2%)  
Others 11 (9.2%) 12 (9.6%)   10 (12.1%) 1 (2.7%)   6 (13.3%) 6 (7.5%)  
Cancer location BC 79 (66.5%) 46 (36.8%) < 0.001 67 (80.7%) 12 (33.3%) < 0.001 32 (71.1%) 14 (17.5%) < 0.001
UTUC 32 (26.8%) 74 (59.2%)   13 (15.7%) 19 (52.8%)   12 (26.7%) 62 (77.5%)  
BC + UTUC 8 (6.7%) 5 (4.0%)   3 (3.6%) 5 (13.9%)   1 (2.2%) 4 (5.0%)  
Surgery No surgery 85 (71.5%) 73 (58.4%) 0.033 63 (75.9%) 22 (61.1%) < 0.001 38 (84.4%) 35 (43.7%) < 0.001
Cystectomy 25 (21.0%) 14 (11.2%)   20 (24.1%) 5 (13.9%)   7 (15.6%) 7 (8.8%)  
Nephroureterectomy 7 (5.8%) 37 (29.6%)   0 (0.0%) 7 (19.4%)   0 (0.0%) 37 (46.3%)  
Cystectomy + nephroureterectomy 2 (1.7%) 1 (0.8%)   0 (0.0%) 2 (5.6%)   0 (0.0%) 1 (1.2%)  
Metastatic site Lymph node 77 (64.7%) 68 (54.4%) 0.10 55 (66.2%) 22 (61.1%) 0.58 33 (73.3%) 35 (43.8%) 0.001
Lung 41 (34.5%) 45 (36.0%) 0.80 23 (12.1%) 18 (50.0%) 0.018 16 (35.6%) 29 (36.3%) 0.94
Liver 24 (20.2%) 18 (14.4%) 0.23 12 (14.5%) 12 (33.3%) 0.018 6 (13.3%) 12 (15.0%) 0.79
Bone 22 (18.5%) 17 (13.6%) 0.29 13 (15.7%) 9 (25.0%) 0.23 6 (13.3%) 11 (13.7%) 0.95
Others 28 (23.5%) 32 (25.6%) 0.70 15 (18.1%) 13 (36.1%) 0.033 9 (20.0%) 23 (28.7%) 0.28
  1. BC bladder cancer, UTUC upper urinary tract urothelial cancer
\